Brief: Cardiff Oncology Announces Positive Clinical Data In Pancreatic Cancer And Small Cell Lung Cancer

Cardiff Oncology

26/09/2023 23:25

Sept 26 (Reuters) - Cardiff Oncology Inc  CRDF.O :
    * CARDIFF ONCOLOGY ANNOUNCES POSITIVE CLINICAL DATA IN
PANCREATIC
CANCER AND SMALL CELL LUNG CANCER, INCLUDING SINGLE-AGENT
ACTIVITY FROM ONVANSERTIB MONOTHERAPY
    * CARDIFF ONCOLOGY: PANCREATIC CANCER PHASE 2 TRIAL OF
ONVANSERTIB
+ SOC IN 2ND-LINE SHOWED GREATER EFFICACY VERSUS. HISTORICAL
CONTROLS WITH ORR OF 19%
    * CARDIFF ONCOLOGY INC: A FIRST-LINE PANCREATIC
INVESTIGATOR-INITIATED TRIAL IS PLANNED TO EVALUATE EFFICACY OF
ONVANSERTIB + SOC
    * CARDIFF ONCOLOGY: DATA FROM SCLC TRIAL IN REFRACTORY
PATIENTS
WITH EXTENSIVE STAGE DISEASE SHOW SINGLE-AGENT ACTIVITY FROM
ONVANSERTIB MONOTHERAPY

Source text for Eikon:  ID:nPn9vXtjZa 
Further company coverage:  CRDF.O 

 ((Reuters.briefs@thomsonreuters.com;))